CASE STUDY Program Challenges Strengthen Partnership PRA Overcomes Activation/Enrollment Delays in Global Multiple Sclerosis TrialsProgram Challenges Strengthen Partnership PRA Overcomes Activation/Enrollment Delays in Global Multiple Sclerosis Trials Drug Class Progression PRA Services Full Service Indication Multiple Sclerosis Drug Class Small Molecules Study Phase III Business Segment Product Registration Classification Global Regions North America Latin America Western Europe Central Europe Eastern Europe Middle East North Africa South Africa Asia Pacific (incl. India) STUDY DESCRIPTION Study 1: A randomized, multi-center, double-blind, placebo-controlled, dose comparison study to determine the efficacy and safety of Study Drug in patients with relapsing-remittin

Join for free to read